Ono Pharmaceutical pays Biohaven $80 million for protein degrader as UK pulls Valneva's chikungunya vaccine

Tokyo-based Ono Pharmaceutical announced it will pay Biohaven $80 million upfront to license a pan‑IgG protein degrader technology.

The agreement gives Ono rights to develop the degrader, while Biohaven retains rights to continue its own development.

In the United Kingdom, regulators have withdrawn the marketing authorization for Valneva's chikungunya vaccine, halting its rollout.

The briefing also noted that ADC Therapeutics, Atrium Therapeutics, Bristol Myers, Novartis and Pfizer each released separate updates, though details were not provided.